FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3157919519> ?p ?o ?g. }

• W3157919519 endingPage "87.e6" @default.
• W3157919519 startingPage "87.e1" @default.
• W3157919519 abstract "Background The effectiveness of amblyopia therapy can be limited by poor adherence. Dichoptic therapies are a new approach, but recent trials have demonstrated difficulty maintaining high adherence over extended periods of at-home treatment. We evaluated the efficacy and adherence of Luminopia One—a dichoptic treatment that applies therapeutic modifications to streaming content chosen by the patient. Methods This single-arm, multicenter prospective pilot study enrolled children aged 4-12 with anisometropic, strabismic, or mixed amblyopia at 10 pediatric ophthalmic and optometric practices across the United States. The therapeutic was prescribed for 1 hour/day, 6 days/week for 12 weeks of at-home use. The primary endpoint was best-corrected visual acuity (BCVA) at the 12-week follow-up visit. Results In total, 90 participants (mean age, 6.7 ± 2.0 years) were enrolled, and 73/90 participants (81%) had prior treatment beyond refractive correction. For those who completed the 12-week visit, mean amblyopic eye BCVA improved from 0.50 logMAR to 0.35 logMAR (1.5 logMAR lines; 95% CI, 1.2-1.8 lines; P < 0.0001). Mean stereoacuity improved by 0.28 log arcsec (95% CI, 0.14-0.42 log arcsec; P < 0.0001). Median adherence was 86% (interquartile range, 70%-97%). Conclusions In our study cohort, adherence over the 12-week study period was high, and participants demonstrated clinically and statistically significant improvements in visual acuity and stereoacuity. The effectiveness of amblyopia therapy can be limited by poor adherence. Dichoptic therapies are a new approach, but recent trials have demonstrated difficulty maintaining high adherence over extended periods of at-home treatment. We evaluated the efficacy and adherence of Luminopia One—a dichoptic treatment that applies therapeutic modifications to streaming content chosen by the patient. This single-arm, multicenter prospective pilot study enrolled children aged 4-12 with anisometropic, strabismic, or mixed amblyopia at 10 pediatric ophthalmic and optometric practices across the United States. The therapeutic was prescribed for 1 hour/day, 6 days/week for 12 weeks of at-home use. The primary endpoint was best-corrected visual acuity (BCVA) at the 12-week follow-up visit. In total, 90 participants (mean age, 6.7 ± 2.0 years) were enrolled, and 73/90 participants (81%) had prior treatment beyond refractive correction. For those who completed the 12-week visit, mean amblyopic eye BCVA improved from 0.50 logMAR to 0.35 logMAR (1.5 logMAR lines; 95% CI, 1.2-1.8 lines; P < 0.0001). Mean stereoacuity improved by 0.28 log arcsec (95% CI, 0.14-0.42 log arcsec; P < 0.0001). Median adherence was 86% (interquartile range, 70%-97%). In our study cohort, adherence over the 12-week study period was high, and participants demonstrated clinically and statistically significant improvements in visual acuity and stereoacuity." @default.
• W3157919519 created "2021-05-10" @default.
• W3157919519 creator A5001383549 @default.
• W3157919519 creator A5001481135 @default.
• W3157919519 creator A5016171528 @default.
• W3157919519 creator A5024121483 @default.
• W3157919519 creator A5026161368 @default.
• W3157919519 creator A5037874183 @default.
• W3157919519 creator A5039793018 @default.
• W3157919519 creator A5041808171 @default.
• W3157919519 creator A5056281745 @default.
• W3157919519 creator A5056330376 @default.
• W3157919519 creator A5058684226 @default.
• W3157919519 creator A5061491582 @default.
• W3157919519 creator A5071497918 @default.
• W3157919519 creator A5076322803 @default.
• W3157919519 creator A5078414657 @default.
• W3157919519 creator A5089629262 @default.
• W3157919519 creator A5013023807 @default.
• W3157919519 date "2021-04-01" @default.
• W3157919519 modified "2023-09-27" @default.
• W3157919519 title "Digital therapeutic improves visual acuity and encourages high adherence in amblyopic children in open-label pilot study" @default.
• W3157919519 cites W1517334262 @default.
• W3157919519 cites W1970624988 @default.
• W3157919519 cites W1973545783 @default.
• W3157919519 cites W1975460162 @default.
• W3157919519 cites W1975845885 @default.
• W3157919519 cites W1999202014 @default.
• W3157919519 cites W2003621613 @default.
• W3157919519 cites W2015655959 @default.
• W3157919519 cites W2024308239 @default.
• W3157919519 cites W2106316662 @default.
• W3157919519 cites W2116650787 @default.
• W3157919519 cites W2124038949 @default.
• W3157919519 cites W2172131290 @default.
• W3157919519 cites W2548543256 @default.
• W3157919519 cites W2554132869 @default.
• W3157919519 cites W2738891826 @default.
• W3157919519 cites W2765546849 @default.
• W3157919519 cites W2801803373 @default.
• W3157919519 cites W2897470875 @default.
• W3157919519 cites W3026959915 @default.
• W3157919519 cites W97765374 @default.
• W3157919519 doi "https://doi.org/10.1016/j.jaapos.2020.11.022" @default.
• W3157919519 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33905837" @default.
• W3157919519 hasPublicationYear "2021" @default.
• W3157919519 type Work @default.
• W3157919519 sameAs 3157919519 @default.
• W3157919519 citedByCount "8" @default.
• W3157919519 countsByYear W31579195192022 @default.
• W3157919519 countsByYear W31579195192023 @default.
• W3157919519 crossrefType "journal-article" @default.
• W3157919519 hasAuthorship W3157919519A5001383549 @default.
• W3157919519 hasAuthorship W3157919519A5001481135 @default.
• W3157919519 hasAuthorship W3157919519A5013023807 @default.
• W3157919519 hasAuthorship W3157919519A5016171528 @default.
• W3157919519 hasAuthorship W3157919519A5024121483 @default.
• W3157919519 hasAuthorship W3157919519A5026161368 @default.
• W3157919519 hasAuthorship W3157919519A5037874183 @default.
• W3157919519 hasAuthorship W3157919519A5039793018 @default.
• W3157919519 hasAuthorship W3157919519A5041808171 @default.
• W3157919519 hasAuthorship W3157919519A5056281745 @default.
• W3157919519 hasAuthorship W3157919519A5056330376 @default.
• W3157919519 hasAuthorship W3157919519A5058684226 @default.
• W3157919519 hasAuthorship W3157919519A5061491582 @default.
• W3157919519 hasAuthorship W3157919519A5071497918 @default.
• W3157919519 hasAuthorship W3157919519A5076322803 @default.
• W3157919519 hasAuthorship W3157919519A5078414657 @default.
• W3157919519 hasAuthorship W3157919519A5089629262 @default.
• W3157919519 hasConcept C118487528 @default.
• W3157919519 hasConcept C119060515 @default.
• W3157919519 hasConcept C119767625 @default.
• W3157919519 hasConcept C126322002 @default.
• W3157919519 hasConcept C141071460 @default.
• W3157919519 hasConcept C168260308 @default.
• W3157919519 hasConcept C168563851 @default.
• W3157919519 hasConcept C188816634 @default.
• W3157919519 hasConcept C203092338 @default.
• W3157919519 hasConcept C2778257484 @default.
• W3157919519 hasConcept C71924100 @default.
• W3157919519 hasConcept C72563966 @default.
• W3157919519 hasConceptScore W3157919519C118487528 @default.
• W3157919519 hasConceptScore W3157919519C119060515 @default.
• W3157919519 hasConceptScore W3157919519C119767625 @default.
• W3157919519 hasConceptScore W3157919519C126322002 @default.
• W3157919519 hasConceptScore W3157919519C141071460 @default.
• W3157919519 hasConceptScore W3157919519C168260308 @default.
• W3157919519 hasConceptScore W3157919519C168563851 @default.
• W3157919519 hasConceptScore W3157919519C188816634 @default.
• W3157919519 hasConceptScore W3157919519C203092338 @default.
• W3157919519 hasConceptScore W3157919519C2778257484 @default.
• W3157919519 hasConceptScore W3157919519C71924100 @default.
• W3157919519 hasConceptScore W3157919519C72563966 @default.
• W3157919519 hasIssue "2" @default.
• W3157919519 hasLocation W31579195191 @default.
• W3157919519 hasOpenAccess W3157919519 @default.
• W3157919519 hasPrimaryLocation W31579195191 @default.
• W3157919519 hasRelatedWork W2090335815 @default.

• next